Binds Eukaryotic Cell Or Component Thereof Or Substance Produced By Said Eukaryotic Cell Patents (Class 424/152.1)
-
Publication number: 20100008931Abstract: The invention relates to the treatment of mycobacterial infections, autoimmune disorders, lymphoproliferative disorders and induction of immunosuppression following transplantation using coronin 1 and modulators of coronin 1. Particular modulators of coronin 1 are compounds which inhibit the production of coronin 1 or the formation of active coronin 1 from a coronin 1 precursor, partly or entirely inactivate coronin 1, inhibit concentration of coronin 1 at the site of T cell activation, or inhibit the coronin 1 mediated signaling pathway downstream of the T cell receptor Examples of such modulators are antibody or antibody fragments, coronin 1 peptide fragments or corresponding phosphopeptides, or anti-sense oligonucleotides, e.g. siRNA or shRNA.Type: ApplicationFiled: March 23, 2007Publication date: January 14, 2010Inventors: Jean Pieters, Rajesh Jayachandran
-
Patent number: 7641901Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.Type: GrantFiled: September 12, 2005Date of Patent: January 5, 2010Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20090324677Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: September 14, 2007Publication date: December 31, 2009Applicant: CREABILIS THERAPEUTICS S.P.A.Inventors: Silvio Traversa, Chiara Lorenzetto, Valentina Mainero, Sebastiano Morena, Silvano Fumero, Luca Beccaria
-
Patent number: 7635473Abstract: The present invention provides formulations for maintaining the stability of A? binding polypeptides, for example, A? antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.Type: GrantFiled: January 27, 2006Date of Patent: December 22, 2009Assignees: Janssen Alzheimer Immunotherapy, WyethInventors: Nicholas W. Warne, Donna Luisi, Angela Kantor
-
Publication number: 20090297438Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PSMA with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for treating cancer.Type: ApplicationFiled: February 17, 2006Publication date: December 3, 2009Inventors: Haichun Huang, David John king, Chin Pan, Josephine M. Cardarelli
-
Publication number: 20090285829Abstract: A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to the prostate-specific antigen, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to homeopathic technology. In order to obtain the antibodies, the prostate-specific antigen isolated from the prostatic tissues of cattle or prepared synthetically is employed; a mixture of various, mostly centesimal, homeopathic dilutions is used. The method of treating diseases of the urogenital sphere consists in using activated forms of ultra-low doses of antibodies to prostate-specific antigen prepared by multiple consecutive dilutions and exposure to external factors.Type: ApplicationFiled: July 14, 2009Publication date: November 19, 2009Inventors: Oleg Iliich Epshtein, Evgeny Danilovich Goldberg, Alexandr Mikhailovich Dygay
-
Publication number: 20090285828Abstract: The invention provides novel compositions, methods, kits, and uses thereof relating to antimetastatic agents useful for treating neoplastic diseases.Type: ApplicationFiled: July 2, 2009Publication date: November 19, 2009Applicant: CALIFORNIA PACIFIC MEDICAL CENTERInventor: Robert DEBS
-
Patent number: 7618624Abstract: A method for regulating the body weight of an animal by feeding it a liposome-encapsulated antibody against lipase.Type: GrantFiled: January 7, 1999Date of Patent: November 17, 2009Assignees: Anitox CorporationInventor: Julio Pimentel
-
Patent number: 7618631Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and EGFR-targeted drugs.Type: GrantFiled: June 16, 2005Date of Patent: November 17, 2009Assignee: Genentech, Inc.Inventor: Mark Sliwkowski
-
Patent number: 7604800Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: May 10, 2005Date of Patent: October 20, 2009Assignee: AbGenomics Coöperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 7597889Abstract: Disclosed are binding molecules which are recombinant polypeptides containing: (i) a binding domain capable of binding a target molecule, and (ii) an effector domain having an amino acid sequence substantially homologous to all or part of a constant domain of a human immunoglobulin heavy chain; characterized in that the binding molecule is capable of binding the target molecule without triggering significant complement dependent lysis, or cell mediated destruction of the target, and more preferably wherein the effector domain is capable of specifically binding FcRn and/or Fc?RIIb. These are generally based on chimeric domains which are derived from two or more human immunoglobulin heavy chain CH2 domains domains. In preferred embodiments the regions 233-236, and 327-331, are modified, as are further residues to render the molecule null allotypic. Also disclosed are nucleic acids, host cells, production processes and materials, and uses. Pharmaceutical preparations are also disclosed.Type: GrantFiled: May 7, 1999Date of Patent: October 6, 2009Assignee: Cambridge Enterprise LimitedInventors: Kathryn Lesley Armour, Michael Ronald Clark, Lorna McLeod Williamson
-
Patent number: 7595051Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin ?v?3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing ?v?3 antagonists.Type: GrantFiled: October 30, 2007Date of Patent: September 29, 2009Assignee: The Scripps Research InstituteInventors: Peter C. Brooks, David A. Cheresh
-
Publication number: 20090238820Abstract: The present invention relates to anti-MAdCAM antibody compositions comprising a chelating agent, and methods of treating inflammatory disease in a subject.Type: ApplicationFiled: March 2, 2006Publication date: September 24, 2009Inventors: Corey M. Allan, Tapan Kanti Das, Scott Steven Ganser, Sandeep Nema, Satish K. Singh, David Li Zeng
-
Publication number: 20090220523Abstract: The present invention relates to compositions and methods for the treatment of diseases and conditions, including ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of the bioactive lipids. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphinxine-1-phosphate (S1P) or lysophosphophatidic acid (LPA).Type: ApplicationFiled: October 27, 2006Publication date: September 3, 2009Inventors: Roger A. Sabbadini, William A. Garland, Glenn L. Stoller
-
Publication number: 20090214524Abstract: The invention relates to regulation of cell cycle checkpoints, and the application of such regulation in the treatment of disease, particularly cancer.Type: ApplicationFiled: December 22, 2003Publication date: August 27, 2009Applicant: Ludwig Institute for Cancer ResearchInventors: Geert J. P. L. Kops, Don W. Cleveland
-
Publication number: 20090196875Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with Alzheimer's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: January 12, 2009Publication date: August 6, 2009Applicant: CELERA CORPORATIONInventors: Michele CARGILL, Andrew GRUPE, Yonghong LI
-
Publication number: 20090191196Abstract: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.Type: ApplicationFiled: December 30, 2008Publication date: July 30, 2009Inventor: Mark B. Pepys
-
Patent number: 7563441Abstract: This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).Type: GrantFiled: April 8, 2005Date of Patent: July 21, 2009Assignee: Hoffman-La Roche Inc.Inventors: Yvo Graus, Jacques Himber, Miranda Jansen-Molenaar, Dorothee Kling, Erhard Kopetzki, Paul Parren, Frank Rebers, Beat Steiner, Anne Stern, Pamela Strein, Kay-Gunnar Stubenrauch, Jan van de Winkel, Martine van Vugt
-
Publication number: 20090169565Abstract: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.Type: ApplicationFiled: February 26, 2009Publication date: July 2, 2009Applicant: Human Genome Sciences, Inc.Inventors: Guo-Liang Yu, Reinhard Ebner, Jian Ni, Craig A. Rosen
-
Patent number: 7553488Abstract: The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by using an anti-S100 polynucleotide or polypeptide inhibitor or antagonist, which is essentially targeted against S100A8, S100A9 or S100A12, alone or in combination with other inhibitors of chemokines or immune modulating products.Type: GrantFiled: June 20, 2003Date of Patent: June 30, 2009Assignee: Université LavalInventors: Philippe A. Tessier, Carle Ryckman, Karen Vandal, Pascal Rouleau
-
Publication number: 20090162357Abstract: Complement is recognized as an important, humoral defense system involved in the innate (nonspecific) recognition and elimination of microbial invaders, other foreign particles or molecules, and antigen-antibody complexes from the body. The present invention makes use of the surprising notion that the handling of lipids by the body, rather than its antimicrobial activity, is the primary and most ancient function of the complement system. Consequently, atherosclerosis as observed in disorders associated with disturbed lipid metabolism (familial combined hyperlipidemia (FCHL), postprandial hyperlipidemia, hypertriglyceridemia with low levels of HDL cholesterol, and insulin resistance associated with type-II diabetes and obesity), is ascribed to either genetic or acquired defects in ancient (activatory and/or regulatory) complement components. Based on this new insight, novel preventive measures and treatment modalities of disturbed lipid metabolism are introduced.Type: ApplicationFiled: June 25, 2008Publication date: June 25, 2009Inventors: Manuel Castro Cabezas, Hans van Dijk, Petronella Maria van
-
Patent number: 7550143Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different.Type: GrantFiled: March 24, 2006Date of Patent: June 23, 2009Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Patent number: 7550568Abstract: The present invention provides monoclonal antibodies that react against high molecular weight melanoma-associated antigen. These antibodies may be used for diagnostic and/or therapeutic purposes.Type: GrantFiled: February 28, 2008Date of Patent: June 23, 2009Assignee: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventor: Soldano Ferrone
-
Publication number: 20090148460Abstract: The present invention relates to exosome-specific ligands and compositions comprising the same. The invention also relates to methods of generating said ligands and compositions, to methods of using said ligands or compositions, e.g., to block the exosome pathway or to detect and/or characterize exosomes in a sample or subject, as well as to the antigens contacted by said ligands or compositions. The application can be used in experimental, research, therapeutic, prophylactic or diagnostic areas.Type: ApplicationFiled: July 7, 2006Publication date: June 11, 2009Inventors: Alain Delcayre, Jean-Bernard Le Pecq
-
Publication number: 20090148461Abstract: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).Type: ApplicationFiled: February 13, 2008Publication date: June 11, 2009Inventors: Yuji Yamazaki, Itaru Urakawa, Hitoshi Yoshida, Yukiko Aono, Takeyoshi Yamashita, Takashi Shimada, Hisashi Hasegawa
-
Publication number: 20090142355Abstract: Methods for the diagnosis and treatment of type 1 diabetes are described. HLA-DQA2 has now been identified as the gene which is primarily responsible for determining whether an individual is susceptible to develop type 1 diabetes. The use of HLA-DQA2 as a target for developing therapeutic and diagnostic targets for treating type 1 diabetes and detecting susceptibility for the disease is disclosed.Type: ApplicationFiled: April 30, 2008Publication date: June 4, 2009Inventor: Chester A. Alper
-
Patent number: 7541032Abstract: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candidaalbicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind Candida albicans both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize Candida in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another Candida receptor on DC. Together, these results demonstrate that C. albicans has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.Type: GrantFiled: September 19, 2003Date of Patent: June 2, 2009Assignee: Stichting Katholieke UniversiteitInventors: Carl Gustav Figdor, Ruurd Torensma
-
Publication number: 20090123413Abstract: The present invention relates to immunotherapy and more specifically concerns the use of immunostimulatory BAT monoclonal antibodies for treatment of a variety of immunodeficiency related diseases and disorders and malfunction or incompetence of the immune system.Type: ApplicationFiled: August 23, 2005Publication date: May 14, 2009Inventors: Britta Hardy, Annat Raiter, Michael Schickler
-
Patent number: 7527786Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: August 21, 2002Date of Patent: May 5, 2009Assignees: The Regents of the University of California, Agensys, Inc.Inventors: Robert E Reiter, Owen N Witte
-
Publication number: 20090104147Abstract: Methods of delivering a cargo moiety to a cell is provided according to embodiments of the present invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the present invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the present invention.Type: ApplicationFiled: May 11, 2007Publication date: April 23, 2009Inventors: Peter Delputte, Hans Nauwynck
-
Publication number: 20090104193Abstract: This invention is in the field of cancer-related genes. Specifically it relates to methods for detecting cancer or the likelihood of developing cancer based on the presence or absence of the SEM A4D gene or proteins encoded by this gene. The invention also provides methods and molecules for upregulating or downregulating the SEMA4D gene.Type: ApplicationFiled: April 7, 2006Publication date: April 23, 2009Inventors: Albert Lai, Abdallah Fanidi, Robert Booher, Christin Tse, Xie Xu, Guoying Yu, Edward Moler, Michael Rowe
-
Publication number: 20090098140Abstract: Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor.Type: ApplicationFiled: April 27, 2007Publication date: April 16, 2009Inventors: Markus Grompe, Philip R. Streeter, Craig Dorrell, Stephanie L. Abraham, Kelsea M. Lanxon-Cookson
-
Publication number: 20090081209Abstract: Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with KIRHy protein-expressing cells, such as acute myelogenous leukemia (AML), are described.Type: ApplicationFiled: February 1, 2008Publication date: March 26, 2009Applicant: NUVELO, INC.Inventors: PETER C.R. EMTAGE, Y. TOM TANG
-
Publication number: 20090074788Abstract: The present invention provides an antibody against a periostin isoform having anti-cell adhesive activity, especially an anti-periostin antibody having the ability to neutralize anti-cell adhesive properties, as well as a prophylactic or therapeutic agent for periostin-related diseases comprising the antibody. The present invention also provides methods for detecting and quantifying the periostin isoform in a sample by using the antibody, as well as a method for diagnosing periostin-related diseases comprising measuring the amount of the periostin isoform by the detection or quantification method.Type: ApplicationFiled: June 26, 2008Publication date: March 19, 2009Applicants: Asubio Pharma Co., Ltd., Osaka UniversityInventors: Yoshiaki Taniyama, Ryuichi Morishita, Naruto Katsuragi
-
Publication number: 20090068173Abstract: A novel CC-chemokine binding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.Type: ApplicationFiled: December 19, 2005Publication date: March 12, 2009Applicant: Laboratoires Serono S.A.Inventors: Amanda Proudfoot, Christine Power, Achim Frauenschuh
-
Patent number: 7501496Abstract: This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.Type: GrantFiled: September 16, 2005Date of Patent: March 10, 2009Assignee: Roche Palo Alto LLCInventors: Joseph Endl, Elsie M. Eugui, Maria Elena Fuentes, Yvo Graus, Aran Frank Labrijn, Martin Lanzendoerfer, Paul Parren, Frank Rebers, Ralf Schumacher, Stefan Seeber, Jan Van De Winkel, Martine Van Vugt
-
Publication number: 20090060921Abstract: Glycan-optimized monoclonal antibodies that specifically bind CD20 antigen and which have improved effector function are provided. The anti-CD20 antibodies of the invention have a glycosylation pattern that results in an antibody composition having predominately the G0 glycoform, and thus comprise N-glycans that lack fucose (i.e., afucosylated) and galactose residues attached thereto. In some embodiments, these anti-CD20 antibodies comprise the light chain and heavy chain sequences of the rituximab anti-CD20 antibody, and thus represent afucosylated rituximab. Methods for producing these glycan-optimized anti-CD20 antibodies are also provided.Type: ApplicationFiled: May 5, 2008Publication date: March 5, 2009Applicant: Biolex Therapeutics, Inc.Inventors: Lynn F. Dickey, Kevin M. Cox, Charles G. Peele, Ming-Bo Wang
-
Patent number: 7498032Abstract: The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.Type: GrantFiled: May 14, 2004Date of Patent: March 3, 2009Assignee: Seattle Genetics, Inc.Inventors: Clay B. Siegall, Alan F. Wahl, Joseph A. Francisco, Henry Perry Fell, Jr.
-
Patent number: 7498030Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and anti-hormonal compounds, such as anti-estrogens.Type: GrantFiled: September 9, 2005Date of Patent: March 3, 2009Assignee: Genetech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7494651Abstract: The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-?1, TGF-?2, and TGF-?3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal.Type: GrantFiled: December 20, 2006Date of Patent: February 24, 2009Assignee: Eli Lilly and CompanyInventors: Bryan Edward Jones, James D. Pancook, Scott William Rowlinson
-
Patent number: 7485296Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: December 21, 2004Date of Patent: February 3, 2009Assignees: The Regents of the University of California, Agensys, Inc.Inventors: Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovits
-
Patent number: 7485302Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies, and chemotherapeutic agents.Type: GrantFiled: May 5, 2006Date of Patent: February 3, 2009Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Publication number: 20090028857Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.Type: ApplicationFiled: July 23, 2008Publication date: January 29, 2009Applicant: CELL GENESYS, INC.Inventors: Betty Li, Karin Jooss, Alan J. Korman
-
Publication number: 20090028851Abstract: The present invention relates to a particularly advantageous antibody, antibody fragment or derivative thereof, which specifically binds to/interacts with at least one epitope of the extracellular or intracellular domain or the mammalian EAG1 ion channel and to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to methods for the preparation of said antibody, antibody fragments or derivatives thereof and to pharmaceutical compositions comprising the same. Furthermore, the use of said antibody, antibody fragment or derivative thereof and also diagnostic compositions comprising said components are disclosed in the specification. The invention also relates to a method of assessing for the presence of EAG1 expressing cells and for a method of blocking EAG1 function in said cells. The invention further relates to a method of treating diseases with the help or said antibody or antibody fragment or derivative thereof.Type: ApplicationFiled: October 4, 2005Publication date: January 29, 2009Applicants: MAXPLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCH, U3 PHARMA AGInventors: Walter Stuhmer, Hendrik Knotgen, David Gomez-Varela, Luis A. Pardo, Mike Rothe, Esther Zwick-Wallasch, Kerstin Dehne
-
Patent number: 7482007Abstract: The present invention describes methods for inhibition angiogenesis in tissues using vitronectin ?v?3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing ?v?3 antagonists.Type: GrantFiled: July 15, 2004Date of Patent: January 27, 2009Assignee: The Scripps, Research InstituteInventors: Peter C. Brooks, David A. Cheresh
-
Patent number: 7482005Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.Type: GrantFiled: March 5, 2007Date of Patent: January 27, 2009Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Publication number: 20090017039Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.Type: ApplicationFiled: August 17, 2007Publication date: January 15, 2009Applicant: BIOGEN IDES MA INCInventors: Sha Mi, R. Blake Pepinsky, Zhaohui Shao
-
Publication number: 20090017032Abstract: Nucleic acids encoding a new family of chemokines, the CX3C family, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.Type: ApplicationFiled: August 26, 2008Publication date: January 15, 2009Inventors: GERARD T. HARDIMAN, Devora L. Rossi, Kevin B. Bacon, J. Fernando Bazan, Thomas J. Schall, Albert Zlotnik
-
Publication number: 20090017041Abstract: The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of ?-amyloid proteins. The antibodies enabled by the teaching of the present invention are particularly useful for the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of diseases and disorders associated with amyloid plaque formation including secondary amyloidosis and age-related amyloidosis including, but not limited to, neurological disorders such as Alzheimer's Disease (AD).Type: ApplicationFiled: June 12, 2008Publication date: January 15, 2009Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
-
Patent number: RE40811Abstract: The invention relates to in vivo peripheralization of CD34+ cells by administering anti-VLA-4 antibodies or anti-VCAM-1 antibodies.Type: GrantFiled: November 15, 1993Date of Patent: June 30, 2009Assignee: Board of Regents of the University of WashingtonInventor: Thalia Papayannopoulou